Revelation Biosciences Inc (REVB) Actualités

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing...

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

-Phase 1b Study in CKD Patients to begin early 2025- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a...

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the...

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the...

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of...

Form 8-K - Current report

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of...

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

-Top-line data forthcoming- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company...